Fisher to Divest $17M Product Line After FTC Inquiry Into Merger with Thermo
Fisher Scientific plans to divest an undisclosed product line after the Federal Trade Commission asked for information about that line as part of its review into Fisher’s planned merger with Thermo Electron, Fisher said this week.
Fisher said the product line is worth $17 million. A call to Fisher was not returned on deadline. A Thermo spokeswoman declined to identify the product line.
According to Fisher, the FTC had asked it and Thermo Electron to provide the commission with additional information about the line, which Fisher described as a “single, minor product line.”
Fisher said the FTC’s request is the second time the government agency has asked for information about the companies’ product lines.
“Thermo and Fisher expect to resolve issues raised by the second request by agreeing to divest a $17 million product line of Fisher's,” Fisher said in a statement.
In May, Fisher and Thermo had announced their $10.6 billion merger plan.
In its statement this week, Fisher also said the companies “expect to obtain termination of the waiting period” under the Hart-Scott-Rodino Antitrust Improvements Act in October.
Thermo and Fisher are also “working cooperatively with the staff of the European Commission in connection with its review of the proposed merger,” Fisher added.
The companies continue to expect the transaction to close in the fourth quarter following shareholder and regulatory approvals. Lori Gorski, a spokeswoman for Thermos, said the FTC request and sale of the Fisher product line is not expected to delay the anticipated closing date of the merger.
GE Wants New Board for Biacore; Biacore Seeks Delisting
Biacore has set a Sept. 7 date for an extraordinary shareholders’ meeting in response to a request by GE Healthcare to replace Biacore’s current board of directors, Biacore announced this week.
GE is seeking to replace Biacore’s board as a result of GE’s agreement to purchase the company for SEK2.9 billion [$408 million].
Biacore’s board also plans to apply for delisting from the Stockholm Stock Exchange’s O-list, the company said. Upon completion of the deal with GE, the company will no longer fulfill the Exchange’s requirements regarding the number of shares that must be publicly owned.
Biosite and Hopitaux Universitaires de Geneve Partner on Kidney Biomarker Research
Biosite and Hopitaux Universitaires de Geneve plan to identify and validate biomarkers for kidney disease, Biosite announced this week.
Under the terms of the agreement, HUG will identify and validate the biomarkers and Biosite will have the rights to develop diagnostic tests using one or more of those biomarkers.
Financial terms of the collaboration were not disclosed.
The research groups of Solange Moll and Denis Hochstrasser from the department of clinical pathology at HUG have discovered more than 10 proteins specific to kidney function that may yield biomarkers for certain kidney conditions, Biosite said in a statement.
Peakadilly Raises $10.6M in Final Series A Financing
Peakadilly announced this week it has raised €8.5 million [$10.6 million] in the final close of its Series A financing, bringing the total raised during this phase of financing to €14.5 million.
Investors in the second close of the Series A round of funding were GIMV, Life Science Partners, KBC Private Equity, and Baekeland Fonds II, the venture capital fund of the Ghent University Association, Peakadilly said.
Peakadilly, a predictive protein biomarker company, said it will use the funds to increase the capacity of its protein biomarker discovery operations based on its proprietary MASStermind technology.
The company also announced the appointment of Jim Van heusden, senior investment manager at GIMV, to its board.
Arcxis Raises $2.25M in Series A Financing
Arcxis, a maker of laboratory systems for disease pathogen detection and clinical diagnostics, announced it has raised $2.25 million in a Series A round of financing. Claremont Creek Ventures was the investor, Arcxis said this week.
Acrxis will use the money for development, testing and commercialization of its products, the company said.
Nanolnk Gets $735K to Develop Nanotech to Enhance Chip-Based Assays
Nanolnk announced last week that it has been awarded a $735,000 Phase II Small Business Innovation Research grant from the National Human Genome Research Institute of the National Institutes of Health.
The grant will be used to “develop novel, biologically functional nanostructures that dramatically enhance the reproducibility, sensitivity, and spatial density of chip-based assays,” the company said in a statement.
“Creation of these nanostructures will improve life science application ranging from point-of-care diagnosis to genomic and proteomic assays used in basic research,” said company CEO Cedric Loiret-Bernal.
Nanolnk, based in Skokie, Ill., specializes in nanometer-scale manufacturing and applications development for the life-sciences and semiconductor industries.
Dole Food Owner to Purchase, Donate Bruker 950 MHz NMR Spectrometer
David Murdock owner of Castle & Cooke and Dole Food Company, announced he will purchase from Bruker BioSpin an Avance II 950 US2 950 meghertz nuclear magnetic resonance spectrometer to donate to the David H. Murdock Research Institute on the North Carolina Research Campus.
According to a statement from the research campus, the spectrometer is the world’s “first and only actively shielded 950 MHz superconducting magnet.”
The two-story, eight-ton machine will allow scientists to look at molecules in 3D “and study their interactions with greater clarity than ever before, significantly enhancing such key areas of research as drug development and nutrition,” the research campus said.
Financial details about the purchase were not disclosed.
The research institute, still in development, will support researchers from the University of North Carolina-Chapel Hill, North Carolina State University, Duke University and other area institutions and scientists.